Skip to main content
68°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sesen Bio
Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update
November 07, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
August 08, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
July 18, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
May 09, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Provides Strategic Update
May 03, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
February 28, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Further Enhances Team with Key Hires
January 10, 2022
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Strengthens Medical Team
November 29, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role
November 23, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update
November 08, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Productive CMC Type A Meeting with the FDA
November 01, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Expands CMC and Clinical Teams
October 12, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
August 13, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™
August 11, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™
August 09, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey
August 05, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US
July 26, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces New Appointments to its Board of Directors
July 21, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China
July 20, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™
July 14, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical
June 02, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Strengthens Senior Leadership Team
June 01, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
May 10, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™
May 04, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021
May 03, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend “FOR” Proposal to Increase Authorized Shares
April 07, 2021
From
Sesen Bio
Via
Business Wire
Tickers
SESN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.